Motoo Ueno, Representative Director, Deputy Chairman

FY2019 1Q Consolidated Financial Overview

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit

New Mid-term Business Plan “IBI 21”

Tatsuro Kosaka,
President and CEO

FY2018 Consolidated Financial Overview (IFRS based)

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit

1. Product Overview of GAZYVA^® Intravenous Infusion 1000 mg

Naoko Oya, GAZYVA^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

2. Pathology of Follicular Lymphoma and Clinical Trial Results of obinutuzumab

Kiyohiko Hatake, M.D., Ph.D.
Deputy Director, Head of the Malignant Tumor and Hematologic Tumor Center at the International University of Health and Welfare, Mita Hospital, Japan

FY2018 3Q Consolidated Financial Overview (IFRS based)

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit

Aiming to Achieve Mid-term Business Plan “IBI 18”
- FY2018 Half Year Results -

Tatsuro Kosaka,
President and CEO

FY2018 2Q Consolidated Financial Overview (IFRS based)

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit

1. HEMLIBRA^® Subcutaneous Injection Product Overview

Hiroshi Motegi, HEMLIBRA^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

2. Current Status of Hemophilia Treatment and Expectations for HEMLIBRA^®

Prof. Midori Shima, M.D., Ph.D.
Department of Pediatrics, Nara Medical University

1. TECENTRIQ^® Intravenous Infusion 1200mg Product Overview

Mikio Sakai, TECENTRIQ^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

2. The Anti-PD-L1 Antibody Tecentriq^® Mode of Action and Future Outlook

Hiroyoshi Nishikawa, M.D., Ph.D.
Department of Immunology, Nagoya University Graduate School of Medicine
Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center

3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq^®

Yuichiro Ohe, M.D.
Deputy Director, Chief,
Division of Thoracic Oncology
National Cancer Center Hospital, Japan

Aiming to Achieve Mid-Term Business Plan “IBI 18”
-2017 Results and 2018 Outlook-

Tatsuro Kosaka, President, COO

FY2017 Consolidated Financial Overview

Yoshio Itaya, Executive Vice President, CFO

Overview of Development Pipeline

Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit

Drastic Changes in the Environment of the New Drug Creation and Challenges Facing Japan’s Pharmaceutical Industry

Chairman and CEO　Osamu Nagayama

FY2017 2Q Consolidated Financial Overview

Yoshio Itaya,
Executive Vice President, CFO

Overview of Development Pipeline

Yasushi Ito,
Senior Vice President, Head of Project & Lifecycle Management Unit

Mid-Term Business Plan “IBI 18”
-2016 Results and 2017 Outlook-

Tatsuro Kosaka, President, COO

FY2016 Consolidated Financial Overview

Yoshio Itaya, Executive Vice President, CFO

Overview of Development Pipeline

Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit

Reorganization to Provide a New Solution

Susumu Kato, Senior Vice President,
General Manager of Marketing & Sales Div.

FY2016 2Q Consolidated Financial Overview

Yoshio Itaya,
Executive Vice President CFO

Overview of Development Pipeline

Minoru Watanabe,
Associate Vice President
Deputy General Manager of Research Division

Outline of the Comprehensive Collaboration Agreement between Osaka University and Chugai Pharmaceutical Co., Ltd.

Executive Vice President of Research and Risk Management, Osaka University
Yasushi Yagi

Outline of Comprehensive Collaboration with IFReC

CHUGAI PHARMACEUTICAL CO., LTD.
Executive Vice President
Yutaka Tanaka

1. Product Overview of Bonviva^® Tablet

Takeshi Sakaguchi
Bonviva^® Product Manager
Chugai Pharmaceutical Co., Ltd.

2. Bonviva^® Tablet: Clinical Utility and Our Expectation

Hiroshi Hagino, M.D., Ph.D., Professor
School of Health Science
Tottori University Faculty of Medicine, Japan

New Mid-Term Business Plan "IBI 18"

Tatsuro Kosaka, President, COO

FY2015 Consolidated Financial Overview

Yoshio Itaya, Executive Vice President, CFO

Overview of Development Pipeline

Yutaka Tanaka, Executive Vice President

FY2015 2Q Consolidated Financial Overview

Yoshio Itaya, Executive Vice President CFO

Overview of Development Pipeline

Yutaka Tanaka, Executive Vice President

1. Overview of ZELBORAF^®

Takahiro Mizui
ZELBORAF^® Lifecycle Leader
CHUGAI PHARMACEUTICAL CO., LTD.

2. cobas^® BRAF V600 Mutation Test

Toru Ogawa
Manager, Molecular Diagnostics
Roche Diagnostics K.K.

3. ZELBORAF^® tablet Postmarketing safety measures

Shin Yoshida
Pharmacovigilance Department
CHUGAI PHARMACEUTICAL CO., LTD.

4．Overview of melanoma and clinical trials of vemurafenib

Naoya Yamazaki, M.D., Ph.D.
Chief, Dept. of Dermatologic Oncology
National Cancer Center Hospital, Japan

Aiming to Become a Top Pharmaceutical Company

Tatsuro Kosaka, President, COO

FY2014 Consolidated Financial Overview

Yoshio Itaya, Executive Vice President, CFO

Overview of Development Pipeline

Yutaka Tanaka, Executive Vice President,
Head of Project & Lifecycle Management Unit